Evaluation of Interferon-gamma Responses to HCMV Infection in HIV Positive Individuals

This study has been completed.

First Received on September 13, 2005. Last Updated on January 19, 2012 History of Changes

Sponsor:	The Alfred
Collaborator:	Cellestis
Information provided by (Responsible Party):	Jennifer Hoy, The Alfred
ClinicalTrials.gov Identifier:	NCT00168259

Purpose

The study is designed to evaluate interferon responses to CMV in HIV positive individuals and a component will look at interferon responses to CMV in HIV positive individuals over time after commencement of antiretroviral therapy. We will also look at the correlation between CD4 T cell numbers and HLA type with the interferon response.

Condition
HIV Infection CMV Infection

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Evaluation of Interferon-gamma Responses to HCMV Infection in HIV Positive Individuals

Resource links provided by NLM:

Genetics Home Reference related topics: complement factor I deficiency

MedlinePlus related topics: Cytomegalovirus Infections HIV/AIDS

Drug Information available for: Interferon gamma-1b Gamma Rays Interferons

U.S. FDA Resources

Further study details as provided by The Alfred:

Biospecimen Retention: Samples With DNA

Plasma, and DNA

Enrollment:	20
Study Start Date:	December 2004
Study Completion Date:	December 2009

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

HIV infected patients with past CMV infection initiating antiretroviral therapy

Criteria

Inclusion Criteria:

HIV positive with history of documented HCV infection
Over 18 years old
HIV positive
Antiretroviral naive, starting on antiretroviral therapy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00168259

Locations

Australia, Victoria
Alfred Hospital
Melbourne, Victoria, Australia, 3004

Sponsors and Collaborators

The Alfred

Cellestis

Investigators

Principal Investigator:

Sharon Lewin, Professor

The Alfred

More Information

No publications provided

Responsible Party:	Jennifer Hoy, Professor Jennifer Hoy, The Alfred
ClinicalTrials.gov Identifier:	NCT00168259 History of Changes
Other Study ID Numbers:	185/04
Study First Received:	September 13, 2005
Last Updated:	January 19, 2012
Health Authority:	Australia: National Health and Medical Research Council

Keywords provided by The Alfred:

Treatment Naive
HIV

Additional relevant MeSH terms:

HIV Infections
Acquired Immunodeficiency Syndrome
Cytomegalovirus Infections
HIV Seropositivity
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases

Slow Virus Diseases
Herpesviridae Infections
DNA Virus Infections
Interferon-gamma
Interferon-gamma, Recombinant
Interferons
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antineoplastic Agents

ClinicalTrials.gov processed this record on February 09, 2012